We recently published a list of 8 Best Gene-Editing Stocks to Buy. In this article, we are going to take a look at where Beam ...

Fintel reports that on March 28, 2025, B of A Securities upgraded their outlook for Beam Therapeutics (NasdaqGS:BEAM) from ...

Biotech stocks plunge after Dr. Peter Marks resigns from FDA, citing disputes with RFK Jr. over vaccines and drug approvals.

Beam Therapeutics Inc.’s BEAM share price has dipped by 11.15%, which has investors questioning if this is right time to buy.

The sudden resignation of Peter Marks, M.D., Ph.D., from the FDA branch that regulates biological products for humans ...

Beam Therapeutics (NASDAQ:BEAM – Get Free Report) was upgraded by equities research analysts at Bank of America from a “neutral” rating to a “buy” rating in a report released on Friday, Marketbeat.com ...

Beam Therapeutics specializes in developing base-edited therapies for rare diseases and cancers. The company’s proprietary base editing platform allows for precise genetic modifications without ...

Beam Therapeutics reported promising Phase 1/2 data for BEAM-302, demonstrating durable gene correction for AATD. See why I ...

The field of gene editing recently got a major boost from Massachusetts-based Beam Therapeutics, and the company’s Durham ...

Beam Therapeutics BEAM has been analyzed by 9 analysts in the last three months, revealing a diverse range of perspectives ...

A month has gone by since the last earnings report for Beam Therapeutics Inc. (BEAM). Shares have lost about 21.4% in that time frame, underperforming the S&P 500. Will the recent negative trend ...

BofA upgraded Beam Therapeutics (BEAM) to Buy from Neutral with a $42 price target Light Up your Portfolio with Spark:Easily identify stocks' ...